Codispensing of Benzodiazepines and Opioids Dangerous in Hemodialysis
Patients on hemodialysis who use opioids concurrently with a short-acting benzodiazepine are especially at risk for early death, a study found.
Opioid-Related Disorder
Nonmedical Opioid Use Linked to Symptoms of Major Depressive Disorder
In the cohort without baseline MDD, baseline nonmedical opioid use was significantly associated with an increased risk of incident depressive symptoms, but not MDD, over 3 years.
Combination Interventions Needed to Tackle Excess Mortality From Extramedical Opioids
Excess mortality occurred as the result of a number of causes, including overdose, injuries, and both infectious and noncommunicable diseases.
Aristada, Vivitrol Access Expanded During COVID-19 Pandemic
Alkermes has decided to expand the number of retail pharmacies and clinics where patients can receive access to Aristada (aripiprazole lauroxil) and Vivitrol (naltrexone extended-release injectable suspension).
Financial Incentives Increase X-Waiver Training, Buprenorphine Prescription Rates
Financial incentives improved X-waiver training completion and buprenorphine prescribing rates in emergency department physicians.
Post-Detox Treatment Lowers Mortality in Opioid Use Disorder
People who receive additional treatment following medically managed opioid withdrawal have reduced mortality compared with those who do not receive treatment.
Physicians Report Low Interest in Opioid Use Disorder Meds
Few primary care physicians report interest in treating patients with opioid use disorder.
Clinical Opinions on the Efficacy of Opioid Use Disorder Medications
Despite conflicting evidence, a third of primary physicians do not perceive OUD medication to be more effective than nonmedication treatment.
Can Alternative Pain Management Reduce Opioid Dependence?
Managing moderate or severe postoperative pain, which affects 75% of patients in the United States, remains a challenge for physicians.
AMA Releases Recommendations for Opioid Use Disorder, Pain During COVID-19
The AMA called for alterations for insurers, including terminating cost-sharing and prior authorization for chronic pain and OUD medications and removing restrictions on Medicaid preferred drug lists.
-
Loading...
-
Loading...
Next post in Opioid-Related Disorder
